Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-bl...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Neuropsychopharmacology (New York, N.Y.) Ročník 47; číslo 6; s. 1180 - 1187
Hlavní autori:	Holze, Friederike, Ley, Laura, Müller, Felix, Becker, Anna M, Straumann, Isabelle, Vizeli, Patrick, Kuehne, Sebastian Silva, Roder, Marc A, Duthaler, Urs, Kolaczynska, Karolina E, Varghese, Nimmy, Eckert, Anne, Liechti, Matthias E
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Nature Publishing Group 01.05.2022
Predmet:	Acute effects Autonomic nervous system Blood pressure Brain-derived neurotrophic factor Cognition Cortisol Double-Blind Method Double-blind studies Female Hallucinogens Healthy Volunteers Heart rate Humans LSD Lysergic Acid Diethylamide Lysergide Male Oxytocin Pharmacokinetics Placebos Plasma levels Prolactin Psilocybin Psilocybin - pharmacology Psychedelic drugs
ISSN:	0893-133X, 1740-634X, 1740-634X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects. The 15 mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30 mg psilocybin. The 200 µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100 µg dose. The 200 µg dose of LSD increased only ratings of ineffability significantly more than 30 mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research.Trial registration: ClinicalTrials.gov identifier: NCT03604744.
AbstractList	Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects. The 15 mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30 mg psilocybin. The 200 µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100 µg dose. The 200 µg dose of LSD increased only ratings of ineffability significantly more than 30 mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research.Trial registration: ClinicalTrials.gov identifier: NCT03604744 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects. The 15 mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30 mg psilocybin. The 200 µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100 µg dose. The 200 µg dose of LSD increased only ratings of ineffability significantly more than 30 mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research.Trial registration: ClinicalTrials.gov identifier: NCT03604744. Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects. The 15 mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30 mg psilocybin. The 200 µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100 µg dose. The 200 µg dose of LSD increased only ratings of ineffability significantly more than 30 mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research.Trial registration: ClinicalTrials.gov identifier: NCT03604744.Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects. The 15 mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30 mg psilocybin. The 200 µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100 µg dose. The 200 µg dose of LSD increased only ratings of ineffability significantly more than 30 mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research.Trial registration: ClinicalTrials.gov identifier: NCT03604744.
Author	Eckert, Anne Liechti, Matthias E Varghese, Nimmy Kuehne, Sebastian Silva Müller, Felix Kolaczynska, Karolina E Becker, Anna M Straumann, Isabelle Roder, Marc A Vizeli, Patrick Ley, Laura Duthaler, Urs Holze, Friederike
Author_xml	– sequence: 1 givenname: Friederike orcidid: 0000-0003-3143-1519 surname: Holze fullname: Holze, Friederike organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 2 givenname: Laura surname: Ley fullname: Ley, Laura organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 3 givenname: Felix surname: Müller fullname: Müller, Felix organization: Psychiatric University Hospital, University of Basel, Basel, Switzerland – sequence: 4 givenname: Anna M surname: Becker fullname: Becker, Anna M organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 5 givenname: Isabelle surname: Straumann fullname: Straumann, Isabelle organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 6 givenname: Patrick orcidid: 0000-0002-5954-4446 surname: Vizeli fullname: Vizeli, Patrick organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 7 givenname: Sebastian Silva surname: Kuehne fullname: Kuehne, Sebastian Silva organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 8 givenname: Marc A surname: Roder fullname: Roder, Marc A organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 9 givenname: Urs orcidid: 0000-0002-7811-3932 surname: Duthaler fullname: Duthaler, Urs organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 10 givenname: Karolina E surname: Kolaczynska fullname: Kolaczynska, Karolina E organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland – sequence: 11 givenname: Nimmy surname: Varghese fullname: Varghese, Nimmy organization: Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland – sequence: 12 givenname: Anne orcidid: 0000-0002-9341-3669 surname: Eckert fullname: Eckert, Anne organization: Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland – sequence: 13 givenname: Matthias E orcidid: 0000-0002-1765-9659 surname: Liechti fullname: Liechti, Matthias E email: matthias.liechti@usb.ch, matthias.liechti@usb.ch organization: Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. matthias.liechti@usb.ch
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35217796$$D View this record in MEDLINE/PubMed
BookMark	eNpdkMuKFTEQhoOMOGdGX8CFBNy4iSapdNJZyniFATcKszvkUvHkkO4cO92Lfg2f2G4cN0JBQX0ffxV1Q67GOiIhLwV_Kzj075oS0GvGpWRcSGuYfEIOwijONKiHK3LgvQUmAB6uyU1rZ85FZ3T_jFxDJ4UxVh_I7w95wjDTUIeLm3KrI62JziekLiwzUkxpw20flrXh9DOHjeRIY8b5tBY35Li5Y6SXlksNq88j3crRWBdfkPmSd1hcQF9ZqOM81VIw0jYvcd3VE7qyRdG2-PO-6zl5mlxp-OKx35Ifnz5-v_vC7r99_nr3_p4FBXxmIQkFLqUuRWGD9RL7aGWM0YrEwWNyoFQPxqDU0SspQcsgnNWmw-A7hFvy5m_uZaq_FmzzccgtYCluxLq0o9QAvdXKmk19_Z96rss0btdtVicV75XcrVeP1uIHjMfLlAc3rcd_34Y_i6GGtQ
CitedBy_id	crossref_primary_10_1016_j_pnpbp_2025_111368 crossref_primary_10_1038_s41398_024_03074_9 crossref_primary_10_1002_cpt_3726 crossref_primary_10_1089_neur_2023_0022 crossref_primary_10_1038_s41386_023_01642_z crossref_primary_10_1136_rapm_2024_105532 crossref_primary_10_1016_j_neubiorev_2023_105381 crossref_primary_10_1080_10508619_2022_2139502 crossref_primary_10_3389_fpsyg_2022_873455 crossref_primary_10_1002_14651858_CD015383_pub2 crossref_primary_10_1177_02698811251319457 crossref_primary_10_1176_appi_ajp_20230682 crossref_primary_10_1038_s41386_024_01972_6 crossref_primary_10_1089_psymed_2024_0011 crossref_primary_10_1038_s41380_024_02743_x crossref_primary_10_1038_s41398_024_03187_1 crossref_primary_10_1007_s40262_025_01544_x crossref_primary_10_1080_09515089_2024_2393690 crossref_primary_10_1080_17425255_2025_2549987 crossref_primary_10_1186_s12888_024_05502_y crossref_primary_10_1080_02791072_2024_2399128 crossref_primary_10_1016_j_biopsych_2022_08_025 crossref_primary_10_1002_cpt_3618 crossref_primary_10_1016_j_genhosppsych_2025_09_003 crossref_primary_10_1089_psymed_2024_0019 crossref_primary_10_1016_j_biopha_2022_113612 crossref_primary_10_1016_j_bpsc_2023_11_003 crossref_primary_10_1016_j_neuropharm_2023_109422 crossref_primary_10_3389_fpsyt_2023_1042440 crossref_primary_10_1111_bph_16466 crossref_primary_10_1021_acschemneuro_5c00247 crossref_primary_10_1016_j_bpsc_2024_01_007 crossref_primary_10_1038_s41386_024_02041_8 crossref_primary_10_1007_s00213_024_06599_5 crossref_primary_10_1523_JNEUROSCI_1121_22_2022 crossref_primary_10_1177_02698811231158245 crossref_primary_10_1016_j_neubiorev_2025_106117 crossref_primary_10_1097_JCP_0000000000001691 crossref_primary_10_37349_en_2025_1006105 crossref_primary_10_1016_j_drugalcdep_2025_112699 crossref_primary_10_1089_psymed_2022_0011 crossref_primary_10_3389_fpsyt_2023_1303365 crossref_primary_10_1007_s00213_023_06517_1 crossref_primary_10_1080_02791072_2023_2201244 crossref_primary_10_1124_pharmrev_121_000514 crossref_primary_10_1038_s41386_023_01648_7 crossref_primary_10_1038_s41398_024_03116_2 crossref_primary_10_1080_02791072_2022_2125467 crossref_primary_10_3390_pharmaceutics17040411 crossref_primary_10_1021_acsptsci_5c00462 crossref_primary_10_1177_02698811241278873 crossref_primary_10_1016_j_nsa_2024_104060 crossref_primary_10_1016_j_euroneuro_2024_07_003 crossref_primary_10_1016_j_medj_2025_100725 crossref_primary_10_3389_fpsyt_2023_1134454 crossref_primary_10_3389_fpsyt_2023_1302559 crossref_primary_10_1016_j_neuroscience_2024_01_001 crossref_primary_10_1016_j_biopsych_2022_09_018 crossref_primary_10_1016_j_nsa_2024_103938 crossref_primary_10_1016_j_psychres_2025_116381 crossref_primary_10_1177_0271678X251323364 crossref_primary_10_1007_s43440_023_00539_4 crossref_primary_10_1186_s12868_024_00903_x crossref_primary_10_1007_s00278_024_00715_8 crossref_primary_10_1177_20451253231172254 crossref_primary_10_1227_neu_0000000000002275 crossref_primary_10_1038_s41598_024_65391_9 crossref_primary_10_1016_j_ejphar_2025_177737 crossref_primary_10_1016_j_neuropharm_2022_109220 crossref_primary_10_1016_j_neubiorev_2025_106178 crossref_primary_10_1038_s41386_023_01609_0 crossref_primary_10_3390_psychoactives4030026 crossref_primary_10_1038_s41398_024_03059_8 crossref_primary_10_1016_j_euroneuro_2023_05_008 crossref_primary_10_1038_s41398_024_02900_4 crossref_primary_10_3389_fphar_2024_1334218 crossref_primary_10_1016_j_pnpbp_2025_111448 crossref_primary_10_1016_j_psychres_2024_115880 crossref_primary_10_1002_cpt_2958 crossref_primary_10_1016_j_jpba_2022_114980 crossref_primary_10_1111_bph_70088 crossref_primary_10_1371_journal_pone_0329411 crossref_primary_10_1007_s40263_023_01008_5 crossref_primary_10_3389_fnhum_2024_1402549 crossref_primary_10_1016_j_euroneuro_2023_12_006 crossref_primary_10_1038_s41386_025_02091_6 crossref_primary_10_1111_adb_13386 crossref_primary_10_1038_s41398_023_02477_4 crossref_primary_10_1007_s00213_025_06772_4 crossref_primary_10_1177_02698811231190865 crossref_primary_10_3389_fpsyt_2024_1485337 crossref_primary_10_1016_j_pnpbp_2025_111279 crossref_primary_10_1002_prp2_1217 crossref_primary_10_1186_s40337_025_01394_9 crossref_primary_10_1177_02698811231179801 crossref_primary_10_1016_j_bpsc_2024_02_001 crossref_primary_10_1038_s41598_025_98202_w crossref_primary_10_1016_j_neubiorev_2022_104793 crossref_primary_10_1177_02698811251330747 crossref_primary_10_1038_s41380_024_02830_z crossref_primary_10_1016_j_neuropharm_2024_110280 crossref_primary_10_1177_02698811221146356 crossref_primary_10_1038_s41380_023_02312_8 crossref_primary_10_1038_s41386_023_01588_2 crossref_primary_10_1177_02698811251330741 crossref_primary_10_1038_s41386_022_01389_z crossref_primary_10_1038_s41386_024_01809_2 crossref_primary_10_1055_a_2261_0745 crossref_primary_10_1055_a_1981_3152 crossref_primary_10_1080_21678421_2024_2441274 crossref_primary_10_1093_ijnp_pyac075 crossref_primary_10_1007_s40262_024_01454_4 crossref_primary_10_1038_s41380_025_03240_5 crossref_primary_10_7554_eLife_84173 crossref_primary_10_1016_j_isci_2024_109631 crossref_primary_10_1016_j_pharmthera_2024_108641 crossref_primary_10_1016_j_neubiorev_2024_105538 crossref_primary_10_1038_s41380_025_03169_9 crossref_primary_10_1176_appi_ajp_20230914 crossref_primary_10_1002_cpt_2821 crossref_primary_10_1177_02698811241276788 crossref_primary_10_3389_fnins_2024_1420601 crossref_primary_10_1016_j_pnpbp_2025_111251 crossref_primary_10_1177_02698811251361453 crossref_primary_10_1038_s41380_024_02439_2 crossref_primary_10_1177_02698811231155117 crossref_primary_10_1038_s41386_023_01607_2 crossref_primary_10_1016_j_neubiorev_2025_106132 crossref_primary_10_1007_s40263_023_01044_1
ContentType	Journal Article
Copyright	2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2M M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8
DOI	10.1038/s41386-022-01297-2
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Psychology Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Psychology MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology
EISSN	1740-634X
EndPage	1187
ExternalDocumentID	35217796
Genre	Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K -DZ -Q- 0R~ 1B1 29N 2WC 36B 39C 4.4 406 53G 5RE 5VS 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AACDK AAEDT AALRI AANZL AAQFI AAQXK AASML AATNV AAXUO AAYZH ABAKF ABBRH ABDBE ABFSG ABIVO ABJNI ABLJU ABMAC ABRTQ ABUWG ABWVN ABZZP ACAOD ACGFO ACGFS ACIUM ACKTT ACMJI ACPRK ACRPL ACRQY ACSTC ACVFH ACZOJ ADBBV ADCNI ADFRT ADMUD ADNMO AEFQL AEJRE AEMSY AENEX AESKC AEUPX AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFPUW AFRAH AFSHS AGAYW AGHAI AGQEE AGQPQ AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG ATHPR AVWKF AYFIA AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DIK DNIVK DPUIP DWQXO E3Z EBLON EBS ECM EE. EIF EIOEI EJD EMB EMOBN F5P FDB FDQFY FEDTE FERAY FGOYB FIGPU FIZPM FSGXE FYUFA GNUQQ GX1 HCIFZ HMCUK HVGLF HYE HZ~ IHE IWAJR JSO JZLTJ KQ8 LGEZI LOTEE M1P M2M M41 M7P MK0 NADUK NPM NQ- NQJWS NXXTH O9- OK1 P2P P6G PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PSYQQ Q2X R2- RIG RNS RNT RNTTT ROL RPM RPZ SEW SNX SNYQT SOHCF SOJ SRMVM SSZ SV3 SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D ZGI ZKB 3V. 7TK 7XB 8FE 8FH 8FK K9. LK8 PKEHL PQEST PQUKI PRINS Q9U 7X8
ID	FETCH-LOGICAL-c430t-cf143aff5fd19c9b2e8d92ddd91f03befa3448377e26db422362c1a9675ecb5e3
IEDL.DBID	M7P
ISICitedReferencesCount	149
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000771073600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0893-133X 1740-634X
IngestDate	Sun Nov 09 14:36:23 EST 2025 Fri Oct 03 10:51:37 EDT 2025 Mon Jul 21 06:05:48 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
License	2022. The Author(s).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c430t-cf143aff5fd19c9b2e8d92ddd91f03befa3448377e26db422362c1a9675ecb5e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ORCID	0000-0002-9341-3669 0000-0002-1765-9659 0000-0003-3143-1519 0000-0002-7811-3932 0000-0002-5954-4446
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC9018810
PMID	35217796
PQID	2652408427
PQPubID	33935
PageCount	8
ParticipantIDs	proquest_miscellaneous_2633896497 proquest_journals_2652408427 pubmed_primary_35217796
PublicationCentury	2000
PublicationDate	2022-05-01
PublicationDateYYYYMMDD	2022-05-01
PublicationDate_xml	– month: 05 year: 2022 text: 2022-05-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: New York
PublicationTitle	Neuropsychopharmacology (New York, N.Y.)
PublicationTitleAlternate	Neuropsychopharmacology
PublicationYear	2022
Publisher	Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group
SSID	ssj0015768
Score	2.6731036
Snippet	Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1180
SubjectTerms	Acute effects Autonomic nervous system Blood pressure Brain-derived neurotrophic factor Cognition Cortisol Double-Blind Method Double-blind studies Female Hallucinogens Healthy Volunteers Heart rate Humans LSD Lysergic Acid Diethylamide Lysergide Male Oxytocin Pharmacokinetics Placebos Plasma levels Prolactin Psilocybin Psilocybin - pharmacology Psychedelic drugs
Title	Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
URI	https://www.ncbi.nlm.nih.gov/pubmed/35217796 https://www.proquest.com/docview/2652408427 https://www.proquest.com/docview/2633896497
Volume	47
WOSCitedRecordID	wos000771073600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB6apJRe-ti0Tdp0UaHkFJG1bEvWqaQloYfuYkpa9rboCYaNvY3XAf-N_uKOZGdzai8FI7AlG4M-jb55aAbgI25aSjsuqTFG0yzxjirJGeU888wgg8-jwe3nN7FYFMulLEeDWzuGVd7LxCiobWOCjfyc8Txk48qY-LT5RUPVqOBdHUto7MFByJKQxtC9cudFCFw6skiZUtTFluOhmVlanLcovIsQfhsCE5gUlP2dYsat5ur5__7kC3g2kkxyMaDiJTxy9QQOL2pUsG96ckpi2Ge0p0_gyXz0rk_gtBzyWPdn5PrhWFZ7Ft_YZbjuD-H3ICiJ2RUxJI0nSCWJMt3WkTFIJDxc94hxlK7YU1liK4fAQBBWFsfWlmzaCnfTHtVzgpcitun02lGN5Bc7g4lfN3QMp187S2I23DB0OL_Zk7bTwZLUvoIfV5fXX77SsbgDNVk621Ljkakp73NvE2mkZq6wkllrZeJnqXZepVnIdi8c41ZnyGI4YgdxJHJndO7S17BfN7U7AlJwL7WWheFOZ4UXKgk5472RqVaCzdQxnNzP1mpcoe3qYaqO4cOuG9dWcJio2jVdGIMKvOSZxDFvBkSsNkMSkBUS10QIyd_---Pv4CmLIAshkiewv73t3Ht4bO62VXs7hT2xFLEtpnDw-XJRfse7OZtPI5CxXZTzP_zm--k
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qBQEbHlMohQJGgq5qdeIkTrxAqAKqVp0ZdTGg2QU_pUjTZGgSUH6DD-EbuU4y0xXsukDKKr6xEufY99j3BfAWlZZUlguqtVY0CpylUnBGOY8c08jg4-7A7eskmc3SxUJcbMHvdSyMd6tcr4ndQm1K7c_IjxiPfTauiCUfVt-prxrlravrEho9LM5t-xO3bNX7s0_4f98xdvJ5_vGUDlUFqI7CcU21Q4ognYudCYQWitnUCGaMEYEbh8o6GUY-zXpiGTcqQvXJ8aXxA5LYahXbEPu9Bbcj3An5UhFTNt1YLTx371irCCnu_RZDkM44TI8qVBapd_f1jhBMJJT9ndJ2qu3k4f82KI_gwUCiyXGP-sewZYsR7BwXsi4vW3JAOrfWzl4wgrvTwXtgBAcXfZ7u9pDMr8POqsPuiU0G73YHfvWKgOhNkUZSOoJUmUjd1JYMTjD-5rLFOYzaA1tyQ0xuEfg4yXKDsoUhqypHttCqvCB4SWLKRi0tVUjusdGbMFRJh3CBpTWky_brRfv41JZUjfInZdUT-HIjI_oUtouysM-ApNwJpUSquVVR6hIZ-Jz4TotQyYSN5R7sr9GRDStQlV1DYw_ebJpx7fAGIVnYsvEyIfJVHgmU2e0RmK36JCcZEvMgSQR__u_OX8O90_l0kk3OZucv4D7rAO7dQfdhu75q7Eu4o3_UeXX1qpsqBL7dNAz_ABm9VW4
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6Vgiou_GwpFAoYCXqq1Y2TOPEBoYqyompZ7aGgvQX_SpGWZGk2oLwGj8PTMXay2xPcekDKKZ5YsjPj-ez5ZgzwGp2WVJYLqrVWNImcpVJwRjlPHNOI4NNw4PblIptO8_lczLbg9zoXxtMq12tiWKhNrf0Z-THjqa_GleBW3Q20iNnp5N3yO_U3SPlI6_o6jV5Fzm33E7dvzduzU_zXbxibfLh8_5EONwxQncTjFdUO4YJ0LnUmElooZnMjmDFGRG4cK-tknPiS65ll3KgEXSnHAeBgstRqldoY-70FtzNftDzQBmebCIbH8QHBipjiPnA-JOyM4_y4QceRe-qvJ0UwkVH2d3gb3Nzk_v88QQ_g3gCuyUlvDQ9hy1Yj2D2p5Kr-1pFDEuiuIY4wgp1PA6tgBIezvn53d0Qur9PRmqPwxaayd7cLv3oHQfTm8kZSO4IQmkjdriwZyDH-5aJD20avgi2lIaa0aBBofKVB2cqQZVMiiuhUWRF8JDF1qxaWKgT92OhDG6qmQxrBwhoSqgB70T5vtSNNq_wJWvMIPt_IjO7BdlVX9gmQnDuhlMg1tyrJXSYjXyvfaRErmbGx3IeDtaYUw8rUFNdqsg-vNs24pvhAkaxs3XqZGHEsTwTKPO61sVj2xU8KBOxRlgn-9N-dv4Qd1L7i4mx6_gzusqDrniV6ANurq9Y-hzv6x6psrl4EqyHw9aa18A__P14_
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Direct+comparison+of+the+acute+effects+of+lysergic+acid+diethylamide+and+psilocybin+in+a+double-blind+placebo-controlled+study+in+healthy+subjects&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Holze+Friederike&rft.au=Ley%2C+Laura&rft.au=M%C3%BCller%2C+Felix&rft.au=Becker%2C+Anna+M&rft.date=2022-05-01&rft.pub=Nature+Publishing+Group&rft.issn=0893-133X&rft.eissn=1740-634X&rft.volume=47&rft.issue=6&rft.spage=1180&rft.epage=1187&rft_id=info:doi/10.1038%2Fs41386-022-01297-2&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon